Becton, Dickinson and Company (NYSE:BDX) Hits New 1-Year High – What’s Next?

Becton, Dickinson and Company (NYSE:BDX)’s stock price reached a new 52-week high on Wednesday. The company traded as high as $205.98 and last traded at $204.7940, with a volume of 113,926 shares changing hands. The stock had previously closed at $198.17.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on BDX shares. Wolfe Research began coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, October 20th. They issued an “outperform” rating on the stock. Bank of America boosted their price target on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Monday, August 31st. Royal Bank Of Canada upped their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research report on Thursday, August 13th. Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Finally, Zacks Research raised Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $185.07.

Becton, Dickinson and Company Trading Up 4.7%

The business has a fifty day moving average of $186.86 and a 200-day moving average of $170.20. The stock has a market capitalization of $57.16 billion, a price-to-earnings ratio of 62.30, a price-to-earnings-growth ratio of 13.39 and a beta of 0.22. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the previous year, the business earned $3.68 earnings per share. Becton, Dickinson and Company’s revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael Feld sold 165 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares in the company, valued at $3,717,022.80. The trade was a 0.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president directly owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 6,907 shares of company stock valued at $1,269,128 in the last quarter. Insiders own 0.40% of the company’s stock.

Institutional Investors Weigh In On Becton, Dickinson and Company

A number of institutional investors and hedge funds have recently modified their holdings of BDX. Brown Lisle Cummings Inc. increased its stake in Becton, Dickinson and Company by 9.2% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier’s stock worth $97,000 after purchasing an additional 54 shares in the last quarter. Pension & Wealth Management Advisors Inc. lifted its stake in Becton, Dickinson and Company by 12.3% during the third quarter. Pension & Wealth Management Advisors Inc. now owns 510 shares of the medical instruments supplier’s stock valued at $94,000 after buying an additional 56 shares in the last quarter. Brighton Jones LLC lifted its stake in Becton, Dickinson and Company by 0.7% during the third quarter. Brighton Jones LLC now owns 8,942 shares of the medical instruments supplier’s stock valued at $1,601,000 after buying an additional 58 shares in the last quarter. Elevation Point Wealth Partners LLC lifted its stake in Becton, Dickinson and Company by 3.7% during the second quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock valued at $256,000 after buying an additional 60 shares in the last quarter. Finally, Private Harbour Investment Management & Counsel LLC lifted its stake in Becton, Dickinson and Company by 1.1% during the second quarter. Private Harbour Investment Management & Counsel LLC now owns 5,511 shares of the medical instruments supplier’s stock valued at $834,000 after buying an additional 62 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.